Abstracts tagged "Abatacept"

Abstract Number: 454 • 2013 ACR/ARHP Annual Meeting
Antibody Response To Pneumococcal and Influenza Vaccination In Patients With Rheumatoid Arthritis Receiving Subcutaneous Abatacept
MC Genovese¹, Clifton O. Bingham III², S Cohen³, Leonard H. Calabrese⁴, JR Curtis⁵, A Block⁶, J Fay⁶, S Kelly⁷, A Luo⁶, D Wong⁶ and R Alten⁸, ¹Stanford University, Palo Alto, CA, ²Johns Hopkins University, Baltimore, MD, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Cleveland Clinic Foundation, Cleveland, OH, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Bristol-Myers Squibb, Plainsboro, NJ, ⁸Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany
Background/Purpose: Previous small studies have suggested that responses to some immunizations may be attenuated by intravenous abatacept but remain clinically meaningful.1,2 We investigated the magnitude…
Abstract Number: 1457 • 2013 ACR/ARHP Annual Meeting
Inhibitory Effect Of Abatacept On Joint Damage In Rheumatoid Arthritis Patients With Or Without Concomitant Methotrexate: A Retrospective Multicenter Analysis Of 12 Months Of Abatacept Treatment In Routine Clinical Practice
Isao Matsushita¹, Hiraku Motomura¹, Eiko Seki¹ and Tomoatsu Kimura², ¹Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan, ²Department of rthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan
Background/Purpose: Abatacept is approved for use with or without methotrexate (MTX). The purpose of this study was to clarify the inhibitory effect of abatacept on…
Abstract Number: 424 • 2013 ACR/ARHP Annual Meeting
2-Year Results From The Ample (Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: Changes In Patient-Reported Outcomes In Response To Subcutaneous Abatacept Or Adalimumab In Rheumatoid Arthritis
Roy Fleischmann¹, ME Weinblatt², M Schiff³, D Khanna⁴, MA Maldonado⁵, A Nadkarni⁶ and Daniel Furst⁷, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ³University of Colorado, Denver, CO, ⁴University of Michigan, Ann Arbor, MI, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Bristol-Myers Squibb, Plainsboro, NJ, ⁷University of California at Los Angeles, Los Angeles, CA
Background/Purpose: RA is a debilitating disease that can impact health-related quality of life (HRQoL) through impairment of activity, loss of independence and reduced work productivity.…
Abstract Number: 1465 • 2013 ACR/ARHP Annual Meeting
Adherence To The Recommended Dosing Regimen Of Abatacept In The Real-World Setting In The Action Study: Is There a Dose-Creep In Overweight Patients?
H Nüßlein¹, R Alten², M Galeazzi³, H M Lorenz⁴, D Boumpas⁵, M T Nurmohamed⁶, W G Bensen⁷, Gerd Burmester⁸, H-H Peter⁹, F Rainer¹⁰, K Pavelka¹¹, M Chartier¹², C Poncet¹³, C Rauch¹⁴ and M Le Bars¹⁵, ¹University Erlangen, Nürnberg, Germany, ²Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital Heidelberg, Heidelberg, Germany, ⁵Panepistimio Kritis, Rethymnon, Greece, ⁶VU University Medical Center/Jan van Breeman Research Institute, Amsterdam, Netherlands, ⁷St. Joseph's Hospital/McMaster University, Hamilton, ON, Canada, ⁸Charité-Universitätsmedizin, Berlin, Germany, ⁹University of Freiburg, Freiburg, Germany, ¹⁰Hospital Barmherzige Brueder, Graz, Austria, ¹¹Institute of Rheumatology, Prague, Czech Republic, ¹²Chiltern International, Neuilly, France, ¹³Docs International, Nanterre, France, ¹⁴Bristol-Myers Squibb, Munich, Germany, ¹⁵Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: Reduced efficacy for achieving DAS28 30 kg/m2,1 which in theory could induce dose increases to maintain efficacy. Here we explore adherence to abatacept over…
Abstract Number: 1442 • 2013 ACR/ARHP Annual Meeting
Three-Year Drug Survival and Effectiveness Of Abatacept and Tocilizumab In Patients with Rheumatoid Arthritis Treated In Routine Care. Results From The Nationwide Danish Danbio Registry
HCB Leffers^1,2, Mikkel Østergaard³, Bente Glintborg⁴, Niels Steen Krogh⁵, Ulrik Tarp⁶, Tove Lorenzen⁷, Annette Hansen⁸, Lene Dreyer⁹ and Merete L. Hetland³, ¹DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Glostrup, Denmark, ²Department of Rheumatology, Frederiksberg Hospital, Frderiksberg, Denmark, ³Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ⁵ZiteLab ApS, Copenhagen, Denmark, ⁶Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁷Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁸Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ⁹Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark
Background/Purpose: Treatment with abatacept and tocilizumab has been shown to be efficacious in rheumatoid arthritis (RA) patients refractory to tumor necrosis factor inhibitor (TNFi). However,…
Abstract Number: 1448 • 2013 ACR/ARHP Annual Meeting
Drug Retention Rates Of Biologic Monotherapies For Patients With Rheumatoid Arthritis In Daily Clinical Practice; Using Multicenter Registry In Japan
Hiroyuki Matsubara¹, Toshihisa Kojima², Masatoshi Hayashi³ and Naoki Ishiguro⁴, ¹Rheumatology, Handa Municipal Hospital, Handa, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ³Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ⁴Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: In general, drug retention rate reflects the effectiveness and tolerability of the drug. In Japan, six biological agents have been approved for the treatment…
Abstract Number: 810 • 2012 ACR/ARHP Annual Meeting
Assessment of Omeract Global Power Doppler Ultrasonography 44-Joint Scoring System and Reduced Joint Scoring Systems in Rheumatoid Arthritis Patients Treated with Abatacept Plus Background Methotrexate
MA D'Agostino¹, R. Wakefield², H. Berner Hammer³, O. Vittecoq⁴, M. Galeazzi⁵, P. Balint⁶, E. Filippucci⁷, I. Moller⁸, A. Iagnocco⁹, E. Naredo¹⁰, Mikkel Ostergaard¹¹, C. Gaillez¹², K. Van Holder¹³, M. Le Bars¹² and OMERACT-US Task Force¹⁴, ¹AP-HP Ambroise Pare Hospital, Boulogne-Billancourt, France, ²University of Leeds, Leeds, United Kingdom, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴University Hospital, Rouen, France, ⁵University of Siena, Siena, Italy, ⁶National Institute, Budapest, Hungary, ⁷University Politecnica delle Marche, Ancona, Italy, ⁸Instituto Poal, Barcelona, Spain, ⁹Sapienza Università di Roma, Roma, Italy, ¹⁰Hospital Severo Ochoa, Madrid, Spain, ¹¹Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ¹²Bristol-Myers Squibb, Rueil Malmaison, France, ¹³Bristol-Myers Squibb, Braine-L’Alleud, Belgium, ¹⁴Paris
Background/Purpose: The first international trial using the standardized global OMERACT Power Doppler Ultrasonography (PDUS) synovitis scoring system1 showed early and significant signs of improvement in…
Abstract Number: 811 • 2012 ACR/ARHP Annual Meeting
The Relationship Between Power Doppler Ultrasonography Outcomes and Clinical Efficacy in Abatacept-Treated Patients with Rheumatoid Arthritis and in Inadequate Response to Methotrexate
MA D'Agostino¹, R. Wakefield², H. Berner Hammer³, O. Vittecoq⁴, M. Galeazzi⁵, P. Balint⁶, E. Filippucci⁷, I. Moller⁸, A. Iagnocco⁹, E. Naredo¹⁰, Mikkel Ostergaard¹¹, C. Gaillez¹², K. Van Holder¹³, M. Le Bars¹² and OMERACT Ultrasound Task Force¹⁴, ¹AP-HP Ambroise Pare Hospital, Boulogne-Billancourt, France, ²University of Leeds, Leeds, United Kingdom, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴University Hospital, Rouen, France, ⁵University of Siena, Siena, Italy, ⁶National Institute, Budapest, Hungary, ⁷University Politecnica delle Marche, Ancona, Italy, ⁸Instituto Poal, Barcelona, Spain, ⁹Sapienza Università di Roma, Roma, Italy, ¹⁰Hospital Severo Ochoa, Madrid, Spain, ¹¹Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ¹²Bristol-Myers Squibb, Rueil Malmaison, France, ¹³Bristol-Myers Squibb, Braine-L’Alleud, Belgium, ¹⁴Paris
Background/Purpose: An exploratory study using the standardized global OMERACT Power Doppler Ultrasonography (PDUS) scoring system1 in patients (pts) with established RA and inadequate response to…
Abstract Number: 460 • 2012 ACR/ARHP Annual Meeting
Real-World Efficacy and Safety of Abatacept Treatment for Rheumatoid Arthritis: 12-Month Interim Analysis of the Action Study
H. Nüßlein¹, R. Alten², M. Galeazzi³, H. M. Lorenz⁴, Dimitrios Boumpas⁵, M. T. Nurmohamed⁶, W. Bensen⁷, Gerd Burmester⁸, H.-H. Peter⁹, F. Rainer¹⁰, Karel Pavelka¹¹, M. Chartier¹², C. Poncet¹³, C. Rauch¹⁴ and M. Le Bars¹⁵, ¹University Erlangen, Nürnberg, Germany, ²Schlosspark-Klinik, University Medicine, Berlin, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital Heidelberg, Heidelberg, Germany, ⁵Panepistimio Kritis, Rethymnon, Greece, ⁶VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands, ⁷St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁸Charité-Universitätsmedizin, Berlin, Germany, ⁹University Medical Center Freiburg, Freiburg, Germany, ¹⁰Hospital Barmherzige Brueder, Graz, Austria, ¹¹Institute of Rheumatology, Prague, Czech Republic, ¹²Chiltern International, Neuilly, France, ¹³Docs International, Sévres, France, ¹⁴Bristol-Myers Squibb, Munich, Germany, ¹⁵Bristol-Myers Squibb, Rueil Malmaison, France
Background/Purpose: Randomized controlled trials (RCTs) of abatacept (ABA) in patients (pts) with RA have demonstrated sustained, long-term efficacy, high pt retention, and consistent safety.1 Data…
Abstract Number: 462 • 2012 ACR/ARHP Annual Meeting
Subcutaneous Abatacept: Long-Term Data From the Acquire Trial
M. C. Genovese¹, C. Pacheco-Tena², A. Covarrubias³, Gustavo Leon⁴, E. Mysler⁵, M. Keiserman⁶, R. Valente⁷, P. Nash⁸, J. A. Simon-Campos⁹, J. Box¹⁰, C. Legerton III¹¹, E. Nasonov¹², P. Durez¹³, I. Delaet¹⁴ and R. Alten¹⁵, ¹Stanford University, Palo Alto, CA, ²Universidad Autónoma de Chihuahua, Chihuahua, Mexico, ³Centro Medico De Las Americas, Merida, Mexico, ⁴Instituto De Ginecologia Y Reproduccion, Lima, Peru, ⁵Organización Médica de Investigación, Buenos Aires, Argentina, ⁶Pontificial Catholic University School of Medicine, Porto Alegre, Brazil, ⁷Arthritis Center of Nebraska, Lincoln, NE, ⁸Rheumatology Research Unit, Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁹Centro De Especialidades Médicas/Universidad Marista, Merida, Mexico, ¹⁰Carolina Bone and Joint, Charlotte, NC, ¹¹Low Country Rheumatology, Charleston, SC, ¹²Institute of Rheumatology, Moscow, Russia, ¹³Université Catholique de Louvain, Brussels, Belgium, ¹⁴Bristol-Myers Squibb, Princeton, NJ, ¹⁵Schlosspark-Klinik, University Medicine, Berlin, Germany
Background/Purpose: The Abatacept (ABA) Comparison of Sub[QU]cutaneous (SC) versus Intravenous (IV) in Inadequate Responders to MethotrexatE (MTX) (ACQUIRE) study showed comparable efficacy and safety of…
Abstract Number: 2449 • 2012 ACR/ARHP Annual Meeting
Head to Head Comparison of Subcutaneous Abatacept Versus Adalimumab in the Treatment of Rheumatoid Arthritis: Key Efficacy and Safety Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
Michael E. Weinblatt¹, Michael H. Schiff², Roy Fleischmann³, Robert Valente⁴, Désirée van der Heijde⁵, Gustavo Citera⁶, Cathy Zhao⁷ and Michael A. Maldonado⁸, ¹Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ²Rheumatology Division, University of Colorado, Denver, CO, ³Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ⁴Arthritis Center of Nebraska, Lincoln, NE, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Medical Strategy, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose : The availability of multiple biologic agents to treat rheumatoid arthritis (RA) has created a need for comparative assessment. AMPLE (Abatacept Versus Adalimumab Comparison…
Abstract Number: 444 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Improves Bone Mineral Density Compared with Abatacept in Patients with TNF Blockers-Resistant Active Rheumatoid Arthritis. an Open Label Randomized Controlled Trial
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada¹, Kazuhiko Hatta², Kuniki Amano³, Noriko Kuwaba⁴ and Hiroyuki Ohta⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²Rheumatology, Hatta Clinic, Kure, Japan, ³Rheumatology, Sky Clinic, Hiroshima, Japan, ⁴Medical Research, Sanki Clinical Link, Hiroshima, Japan, ⁵Medical Research, hiroshima clinic, Hiroshima, Japan
Background/Purpose: To compare the effect of tocilizumab(TCZ) plus methotrexate (MTX), with the effect of abatacept(ABT) plus MTX on bone mineral density(BMD) in TNF blockers resistant…
Abstract Number: 2465 • 2012 ACR/ARHP Annual Meeting
Seroresponse Rates After Influenza Vaccination in Rheumatoid Arthritis Patients Treated with Biological Agents During the 2011–2012 Flu Season
Masatoshi Hayashi¹, Toshihisa Kojima², Naoki Ishiguro³, Tomonori Kobayakawa⁴ and Toshihisa Kanamono¹, ¹Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya Univeristy, School of Medicine, Nagoya, Japan, ³Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, ⁴Orthopedic Surgery, Nagoya university, Nagoya, Japan
Background/Purpose: At present, annual vaccination against influenza is recommended for rheumatoid arthritis (RA) patients. However, whether humoral responses to influenza vaccine are impaired in RA…
Abstract Number: 350 • 2012 ACR/ARHP Annual Meeting
Reduction of Inflammation with Abatacept and Tocilizumab Results in Lower N-Terminal Pro Brain Natriuretic Peptide Levels in Patients with Rheumatoid Arthritis: Results From Prospective Cohort Studies
Inge A.M. van den Oever and Mike T. Nurmohamed, Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of heart failure (HF). The chronic inflammatory state in RA is associated with increased levels of…
Abstract Number: 2163 • 2012 ACR/ARHP Annual Meeting
Abatacept Monotherapy Effectively Reduces the Frequency of Osteoclast Precursor Cells in the Peripheral Blood of Patients with Rheumatoid Arthritis and Inhibits Their Differentiation Into Osteoclasts
Sandra Mueller-Schmucker¹, Roland Axmann¹, Sonja Herman², Mario Zaiss¹, Manuela Le Bars³, Thomas Harrer¹ and Georg A. Schett⁴, ¹University of Erlangen-Nuremberg, Erlangen, Germany, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Bristol-Myers Squibb, Rueil Malmaison, France, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Bone resorbing osteoclasts origin from monocytes. We have recently shown that binding of abatacept (CTLA4-Ig) to CD80 and CD86 on the surface of monocytes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].